Abstract
In today's Lancet, Frank Buttgereit and colleagues report a double-blind randomised trial of modified-release prednisone for rheumatoid arthritis. 1 Buttgereit F Doering G Schaeffler A et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008; 371: 205-214 Summary Full Text Full Text PDF PubMed Scopus (288) Google Scholar The tablets release the drug about 4 h after ingestion (a special coating bursts due to penetration of water). The tablets are ingested in the evening and thus prednisone release is adapted to the circadian rhythm of cortisol. In the study, the duration of early morning stiffness was lower than when the same dose of prednisone (standard pill) was taken early in the morning. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trialModified-release prednisone is well tolerated, convenient to administer, and produces a clinically relevant reduction of morning stiffness of the joints in addition to all known therapeutic effects of immediate-release prednisone. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
